fda glp-1 compounding enforcement september 2025 is short-sighted on GLP-1s Why the FDA Issued 30

Saxenda is specifically indicated for use in adults with obesity (with a body mass index BMIof 30 kg/m2 or greater) or overweight adults (a BMI of 27 kg/m2 or greater) who also have weight-related health conditions such as hypertension (high blood pressure), high cholesterol, or obstructive sleep apnea

Use the to log each dose and track your response over time

John Wilding, professor of medicine in the Department of Cardiovascular and Metabolic Medicine at the University of Liverpool, said this was unsurprising, adding: Obesity is a chronic disease that usually relapses when treatment is stopped. Tricia Tan, professor of metabolic medicine, diabetes and endocrinology at Imperial College London/Imperial College Healthcare NHS Trust, said: There is increasing evidence that structured exercise is important to prevent weight regain after cessation of weight-loss drugs, but noted that this was not discussed in the study

Our findings from perifusion experiments were consistent with those obtained from the static analysis